| Page 8 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria

Author(s): 
Koschmieder S, Panse J
Primary Author: 
Koschmieder S, Panse J
Journal Title: 
Hamostaseologie
Original Publication Date: 
Feb 2025

Patients with thrombosis at an unusual site will need to be explored for rare causes of thrombosis. Two of these rare causes include myeloproliferative neoplasms (MPNs) and

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates

Author(s): 
da Fonseca AR, Justino CC, Campos de Molla V, Yamakawa PE, Rabelo IB, Arnold L, Kelly R, Griffin M, Munir T, Hill A, Velloso E, Dalessandro T, Risitano AM, Scheinberg P, Kulasekararaj A, Arrais-Rodrigues C
Primary Author: 
da Fonseca AR
Journal Title: 
Blood Advances
Original Publication Date: 
Feb 2025

Immunosuppressive therapy using horse antithymocyte globulin (ATG; h-ATG) combined with cyclosporine (CsA) and eltrombopag is the standard care for

Bone Marrow Disease(s): 

Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT

For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis.